USA CINV Existing and Pipeline Drugs Market Professional Research Report 2022-2027, Segmented by Players, Types, End-Users in Major Regions

  • REPORT SUMMARY
  • TABLE OF CONTENTS
  • Nausea and vomiting are the two most common side effects associated with cancer chemotherapy, and are referred to as chemotherapy induced nausea and vomiting (CINV).

    This report offers an overview of the market trends, drivers, and barriers with respect to the USA CINV Existing and Pipeline Drugs market. It also provides a detailed overview of the market of different regions across West USA, South USA, Middle West USA, Northeast USA. The report deeply analyzes type and application in the USA CINV Existing and Pipeline Drugs market. Detailed analysis of key players, along with key growth strategies adopted by CINV Existing and Pipeline Drugs industry, the PEST and SWOT analysis are also included. In short, the report will provide a comprehensive view of the industry's development and features.

    By Player:

    • Merck

    • GlaxoSmithKline

    • Heron Therapeutics

    • Tesaro

    • Helsinn

    By Type:

    • Aloxi (palonosetron)

    • Zofran Generic (ondansetron)

    • Kytril Generic (granisetron)

    • Emend (aprepitant)

    • Akynzeo (netupitant-palonosetron)

    • SUSTOL (extended release granisetron injection)

    • Rolapitant

    By End-User:

    • Hospitals

    • Specialty Clinics

    • Diagnostic Centers Therapeutics

    • Hospital Pharmacies

    • Drugstores

    By Region:

    • West USA

    • South USA

    • Middle West USA

    • Northeast USA

  • TABLE OF CONTENT

    1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of CINV Existing and Pipeline Drugs Market

    • 1.3 Market Segment by Type

      • 1.3.1 USA CINV Existing and Pipeline Drugs Market Size and Growth Rate of Aloxi (palonosetron) from 2016 to 2027

      • 1.3.2 USA CINV Existing and Pipeline Drugs Market Size and Growth Rate of Zofran Generic (ondansetron) from 2016 to 2027

      • 1.3.3 USA CINV Existing and Pipeline Drugs Market Size and Growth Rate of Kytril Generic (granisetron) from 2016 to 2027

      • 1.3.4 USA CINV Existing and Pipeline Drugs Market Size and Growth Rate of Emend (aprepitant) from 2016 to 2027

      • 1.3.5 USA CINV Existing and Pipeline Drugs Market Size and Growth Rate of Akynzeo (netupitant-palonosetron) from 2016 to 2027

      • 1.3.6 USA CINV Existing and Pipeline Drugs Market Size and Growth Rate of SUSTOL (extended release granisetron injection) from 2016 to 2027

      • 1.3.7 USA CINV Existing and Pipeline Drugs Market Size and Growth Rate of Rolapitant from 2016 to 2027

    • 1.4 Market Segment by Application

      • 1.4.1 USA CINV Existing and Pipeline Drugs Market Size and Growth Rate of Hospitals from 2016 to 2027

      • 1.4.2 USA CINV Existing and Pipeline Drugs Market Size and Growth Rate of Specialty Clinics from 2016 to 2027

      • 1.4.3 USA CINV Existing and Pipeline Drugs Market Size and Growth Rate of Diagnostic Centers Therapeutics from 2016 to 2027

      • 1.4.4 USA CINV Existing and Pipeline Drugs Market Size and Growth Rate of Hospital Pharmacies from 2016 to 2027

      • 1.4.5 USA CINV Existing and Pipeline Drugs Market Size and Growth Rate of Drugstores from 2016 to 2027

    • 1.5 Market Segment by Regions

      • 1.5.1 West USA CINV Existing and Pipeline Drugs Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.2 South USA CINV Existing and Pipeline Drugs Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.3 Middle West USA CINV Existing and Pipeline Drugs Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.4 Northeast USA CINV Existing and Pipeline Drugs Consumption Market Size and Growth Rate from 2016 to 2027

    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants

    • 2.3 Coronavirus (COVID-19) Distribution and its Impact on the Industry

    3 Segmentation of CINV Existing and Pipeline Drugs Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Products Types of Major Vendors

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of CINV Existing and Pipeline Drugs by Major Types

      • 3.4.1 Market Size and Growth Rate of Aloxi (palonosetron)

      • 3.4.2 Market Size and Growth Rate of Zofran Generic (ondansetron)

      • 3.4.3 Market Size and Growth Rate of Kytril Generic (granisetron)

      • 3.4.4 Market Size and Growth Rate of Emend (aprepitant)

      • 3.4.5 Market Size and Growth Rate of Akynzeo (netupitant-palonosetron)

      • 3.4.6 Market Size and Growth Rate of SUSTOL (extended release granisetron injection)

      • 3.4.7 Market Size and Growth Rate of Rolapitant

    4 Segmentation of CINV Existing and Pipeline Drugs Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of CINV Existing and Pipeline Drugs by Major End-Users

      • 4.4.1 Market Size and Growth Rate of CINV Existing and Pipeline Drugs in Hospitals

      • 4.4.2 Market Size and Growth Rate of CINV Existing and Pipeline Drugs in Specialty Clinics

      • 4.4.3 Market Size and Growth Rate of CINV Existing and Pipeline Drugs in Diagnostic Centers Therapeutics

      • 4.4.4 Market Size and Growth Rate of CINV Existing and Pipeline Drugs in Hospital Pharmacies

      • 4.4.5 Market Size and Growth Rate of CINV Existing and Pipeline Drugs in Drugstores

    5 Market Analysis by Regions

    • 5.1 USA CINV Existing and Pipeline Drugs Production Analysis by Regions

    • 5.2 USA CINV Existing and Pipeline Drugs Consumption Analysis by Regions

    • 5.3 Coronavirus (COVID-19) Impact on USA Economy

    6 West USA CINV Existing and Pipeline Drugs Landscape Analysis

    • 6.1 West USA CINV Existing and Pipeline Drugs Landscape Analysis by Major Types

    • 6.2 West USA CINV Existing and Pipeline Drugs Landscape Analysis by Major End-Users

    7 South USA CINV Existing and Pipeline Drugs Landscape Analysis

    • 7.1 South USA CINV Existing and Pipeline Drugs Landscape Analysis by Major Types

    • 7.2 South USA CINV Existing and Pipeline Drugs Landscape Analysis by Major End-Users

    8 Middle West USA CINV Existing and Pipeline Drugs Landscape Analysis

    • 8.1 Middle West USA CINV Existing and Pipeline Drugs Landscape Analysis by Major Types

    • 8.2 Middle West USA CINV Existing and Pipeline Drugs Landscape Analysis by Major End-Users

    9 Northeast USA CINV Existing and Pipeline Drugs Landscape Analysis

    • 9.1 Northeast USA CINV Existing and Pipeline Drugs Landscape Analysis by Major Types

    • 9.2 Northeast USA CINV Existing and Pipeline Drugs Landscape Analysis by Major End-Users

    10 Major Players Profiles

      • 10.1 Merck

        • 10.1.1 Merck Company Profile and Recent Development

        • 10.1.2 Market Performance

        • 10.1.3 Product and Service Introduction

      • 10.2 GlaxoSmithKline

        • 10.2.1 GlaxoSmithKline Company Profile and Recent Development

        • 10.2.2 Market Performance

        • 10.2.3 Product and Service Introduction

      • 10.3 Heron Therapeutics

        • 10.3.1 Heron Therapeutics Company Profile and Recent Development

        • 10.3.2 Market Performance

        • 10.3.3 Product and Service Introduction

      • 10.4 Tesaro

        • 10.4.1 Tesaro Company Profile and Recent Development

        • 10.4.2 Market Performance

        • 10.4.3 Product and Service Introduction

      • 10.5 Helsinn

        • 10.5.1 Helsinn Company Profile and Recent Development

        • 10.5.2 Market Performance

        • 10.5.3 Product and Service Introduction

    The List of Tables and Figures

    • Figure Product Picture

    • Figure USA CINV Existing and Pipeline Drugs Market Size and Growth Rate of Aloxi (palonosetron) from 2016 to 2027

    • Figure USA CINV Existing and Pipeline Drugs Market Size and Growth Rate of Zofran Generic (ondansetron) from 2016 to 2027

    • Figure USA CINV Existing and Pipeline Drugs Market Size and Growth Rate of Kytril Generic (granisetron) from 2016 to 2027

    • Figure USA CINV Existing and Pipeline Drugs Market Size and Growth Rate of Emend (aprepitant) from 2016 to 2027

    • Figure USA CINV Existing and Pipeline Drugs Market Size and Growth Rate of Akynzeo (netupitant-palonosetron) from 2016 to 2027

    • Figure USA CINV Existing and Pipeline Drugs Market Size and Growth Rate of SUSTOL (extended release granisetron injection) from 2016 to 2027

    • Figure USA CINV Existing and Pipeline Drugs Market Size and Growth Rate of Rolapitant from 2016 to 2027

    • Figure Market Share by Type in 2016

    • Figure Market Share by Type in 2020

    • Figure Market Share by Type in 2027

    • Figure USA CINV Existing and Pipeline Drugs Market Size and Growth Rate of Hospitals from 2016 to 2027

    • Figure USA CINV Existing and Pipeline Drugs Market Size and Growth Rate of Specialty Clinics from 2016 to 2027

    • Figure USA CINV Existing and Pipeline Drugs Market Size and Growth Rate of Diagnostic Centers Therapeutics from 2016 to 2027

    • Figure USA CINV Existing and Pipeline Drugs Market Size and Growth Rate of Hospital Pharmacies from 2016 to 2027

    • Figure USA CINV Existing and Pipeline Drugs Market Size and Growth Rate of Drugstores from 2016 to 2027

    • Figure Market Share by End-User in 2016

    • Figure Market Share by End-User in 2020

    • Figure Market Share by End-User in 2027

    • Figure West USA CINV Existing and Pipeline Drugs Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure South USA CINV Existing and Pipeline Drugs Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Middle West USA CINV Existing and Pipeline Drugs Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Northeast USA CINV Existing and Pipeline Drugs Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Development Trends and Industry Dynamics of CINV Existing and Pipeline Drugs Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 3 Players in 2019

    • Figure Market Share of TOP 5 Players in 2019

    • Figure Market Share of TOP 6 Players from 2016 to 2020

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Figure Coronavirus (COVID-19) Distribution Map of USA

    • Table Coronavirus (COVID-19) Impact on the Industry

    • Figure Specifications of Different Types of CINV Existing and Pipeline Drugs

    • Figure Development Trends of Different Types

    • Table Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of CINV Existing and Pipeline Drugs by Different Types from 2016 to 2027

    • Table Consumption Share of CINV Existing and Pipeline Drugs by Different Types from 2016 to 2027

    • Figure Market Size and Growth Rate of Aloxi (palonosetron)

    • Figure Market Size and Growth Rate of Zofran Generic (ondansetron)

    • Figure Market Size and Growth Rate of Kytril Generic (granisetron)

    • Figure Market Size and Growth Rate of Emend (aprepitant)

    • Figure Market Size and Growth Rate of Akynzeo (netupitant-palonosetron)

    • Figure Market Size and Growth Rate of SUSTOL (extended release granisetron injection)

    • Figure Market Size and Growth Rate of Rolapitant

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Figure Consumption of CINV Existing and Pipeline Drugs by Different End-Users from 2016 to 2027

    • Table Consumption Share of CINV Existing and Pipeline Drugs by Different End-Users from 2016 to 2027

    • Figure Market Size and Growth Rate of Hospitals

    • Figure Market Size and Growth Rate of Specialty Clinics

    • Figure Market Size and Growth Rate of Diagnostic Centers Therapeutics

    • Figure Market Size and Growth Rate of Hospital Pharmacies

    • Figure Market Size and Growth Rate of Drugstores

    • Table USA CINV Existing and Pipeline Drugs Production by Regions

    • Table USA CINV Existing and Pipeline Drugs Production Share by Regions

    • Figure USA CINV Existing and Pipeline Drugs Production Share by Regions in 2016

    • Figure USA CINV Existing and Pipeline Drugs Production Share by Regions in 2021

    • Figure USA CINV Existing and Pipeline Drugs Production Share by Regions in 2027

    • Table USA CINV Existing and Pipeline Drugs Consumption by Regions

    • Table USA CINV Existing and Pipeline Drugs Consumption Share by Regions

    • Figure USA CINV Existing and Pipeline Drugs Consumption Share by Regions in 2016

    • Figure USA CINV Existing and Pipeline Drugs Consumption Share by Regions in 2021

    • Figure USA CINV Existing and Pipeline Drugs Consumption Share by Regions in 2027

    • Table West USA CINV Existing and Pipeline Drugs Consumption by Types from 2016 to 2027

    • Table West USA CINV Existing and Pipeline Drugs Consumption Share by Types from 2016 to 2027

    • Figure West USA CINV Existing and Pipeline Drugs Consumption Share by Types in 2016

    • Figure West USA CINV Existing and Pipeline Drugs Consumption Share by Types in 2021

    • Figure West USA CINV Existing and Pipeline Drugs Consumption Share by Types in 2027

    • Table West USA CINV Existing and Pipeline Drugs Consumption by End-Users from 2016 to 2027

    • Table West USA CINV Existing and Pipeline Drugs Consumption Share by End-Users from 2016 to 2027

    • Figure West USA CINV Existing and Pipeline Drugs Consumption Share by End-Users in 2016

    • Figure West USA CINV Existing and Pipeline Drugs Consumption Share by End-Users in 2021

    • Figure West USA CINV Existing and Pipeline Drugs Consumption Share by End-Users in 2027

    • Table South USA CINV Existing and Pipeline Drugs Consumption by Types from 2016 to 2027

    • Table South USA CINV Existing and Pipeline Drugs Consumption Share by Types from 2016 to 2027

    • Figure South USA CINV Existing and Pipeline Drugs Consumption Share by Types in 2016

    • Figure South USA CINV Existing and Pipeline Drugs Consumption Share by Types in 2021

    • Figure South USA CINV Existing and Pipeline Drugs Consumption Share by Types in 2027

    • Table South USA CINV Existing and Pipeline Drugs Consumption by End-Users from 2016 to 2027

    • Table South USA CINV Existing and Pipeline Drugs Consumption Share by End-Users from 2016 to 2027

    • Figure South USA CINV Existing and Pipeline Drugs Consumption Share by End-Users in 2016

    • Figure South USA CINV Existing and Pipeline Drugs Consumption Share by End-Users in 2021

    • Figure South USA CINV Existing and Pipeline Drugs Consumption Share by End-Users in 2027

    • Table Middle West USA CINV Existing and Pipeline Drugs Consumption by Types from 2016 to 2027

    • Table Middle West USA CINV Existing and Pipeline Drugs Consumption Share by Types from 2016 to 2027

    • Figure Middle West USA CINV Existing and Pipeline Drugs Consumption Share by Types in 2016

    • Figure Middle West USA CINV Existing and Pipeline Drugs Consumption Share by Types in 2021

    • Figure Middle West USA CINV Existing and Pipeline Drugs Consumption Share by Types in 2027

    • Table Middle West USA CINV Existing and Pipeline Drugs Consumption by End-Users from 2016 to 2027

    • Table Middle West USA CINV Existing and Pipeline Drugs Consumption Share by End-Users from 2016 to 2027

    • Figure Middle West USA CINV Existing and Pipeline Drugs Consumption Share by End-Users in 2016

    • Figure Middle West USA CINV Existing and Pipeline Drugs Consumption Share by End-Users in 2021

    • Figure Middle West USA CINV Existing and Pipeline Drugs Consumption Share by End-Users in 2027

    • Table Northeast USA CINV Existing and Pipeline Drugs Consumption by Types from 2016 to 2027

    • Table Northeast USA CINV Existing and Pipeline Drugs Consumption Share by Types from 2016 to 2027

    • Figure Northeast USA CINV Existing and Pipeline Drugs Consumption Share by Types in 2016

    • Figure Northeast USA CINV Existing and Pipeline Drugs Consumption Share by Types in 2021

    • Figure Northeast USA CINV Existing and Pipeline Drugs Consumption Share by Types in 2027

    • Table Northeast USA CINV Existing and Pipeline Drugs Consumption by End-Users from 2016 to 2027

    • Table Northeast USA CINV Existing and Pipeline Drugs Consumption Share by End-Users from 2016 to 2027

    • Figure Northeast USA CINV Existing and Pipeline Drugs Consumption Share by End-Users in 2016

    • Figure Northeast USA CINV Existing and Pipeline Drugs Consumption Share by End-Users in 2021

    • Figure Northeast USA CINV Existing and Pipeline Drugs Consumption Share by End-Users in 2027

    • Table Company Profile and Development Status of Merck

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Merck

    • Figure Sales and Growth Rate Analysis of Merck

    • Figure Revenue and Market Share Analysis of Merck

    • Table Product and Service Introduction of Merck

    • Table Company Profile and Development Status of GlaxoSmithKline

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of GlaxoSmithKline

    • Figure Sales and Growth Rate Analysis of GlaxoSmithKline

    • Figure Revenue and Market Share Analysis of GlaxoSmithKline

    • Table Product and Service Introduction of GlaxoSmithKline

    • Table Company Profile and Development Status of Heron Therapeutics

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Heron Therapeutics

    • Figure Sales and Growth Rate Analysis of Heron Therapeutics

    • Figure Revenue and Market Share Analysis of Heron Therapeutics

    • Table Product and Service Introduction of Heron Therapeutics

    • Table Company Profile and Development Status of Tesaro

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Tesaro

    • Figure Sales and Growth Rate Analysis of Tesaro

    • Figure Revenue and Market Share Analysis of Tesaro

    • Table Product and Service Introduction of Tesaro

    • Table Company Profile and Development Status of Helsinn

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Helsinn

    • Figure Sales and Growth Rate Analysis of Helsinn

    • Figure Revenue and Market Share Analysis of Helsinn

    • Table Product and Service Introduction of Helsinn


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.